Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | OR2805 |
Trade Name | |
Synonyms | OR-2805|OR 2805 |
Drug Descriptions |
OR2805 is a human IgG1 antibody that targets and binds to CD163 expressed on tumor associated macrophages, potentially resulting in an enhanced antitumor immune response, increased activation and proliferation of T lymphocytes, and T-cell mediated tumor cell death (Cancer Res 2021;81(13_Suppl):Abstract nr 1719). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C185133 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Nivolumab + OR2805 | Nivolumab OR2805 | 0 | 1 |
OR2805 | OR2805 | 0 | 1 |
OR2805 + Pembrolizumab | OR2805 Pembrolizumab | 0 | 1 |